Next Article in Journal
On Forgotten Topological Indices of Some Dendrimers Structure
Next Article in Special Issue
Novel Sulfamide-Containing Compounds as Selective Carbonic Anhydrase I Inhibitors
Previous Article in Journal
Biosynthesis of ZnO Nanoparticles by a New Pichia kudriavzevii Yeast Strain and Evaluation of Their Antimicrobial and Antioxidant Activities
Previous Article in Special Issue
Novel Sulfamethoxazole Ureas and Oxalamide as Potential Antimycobacterial Agents
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 22
Issue 6
10.3390/molecules22060793
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Secondary Sulfonamides as Effective Lactoperoxidase Inhibitors

by
Zeynep Köksal
1,
Ramazan Kalin
2,3,
Yasemin Camadan
4,
Hande Usanmaz
5,
Züleyha Almaz
6,
İlhami Gülçin
2,*,
Taner Gokcen
7,8,
Ahmet Ceyhan Gören
7 and
Hasan Ozdemir
2
1
Department of Chemistry, Faculty of Sciences, İstanbul Medeniyet University, 34730 İstanbul, Turkey
2
Department of Chemistry, Faculty of Science, Ataturk University, 25240 Erzurum, Turkey
3
Department of Basic Science, Faculty of Science, Erzurum Technical University, 25240 Erzurum, Turkey
4
Pharmacy Services Program, Vocational School of Health Services, Artvin Coruh University, 08000 Artvin, Turkey
5
Department of Bioengineering, Faculty of Engineering and Architecture, Sinop University, 57000 Sinop, Turkey
6
Department of Molecular Biology and Genetics, Faculty of Sciences and Arts, Muş Alparslan University, 49250 Muş, Turkey
7
TUBITAK UME, Chemistry Group Laboratories, P.O. Box: 54, 41470 Gebze Kocaeli, Turkey
8
Department of Organic Chemistry, Faculty of Science, Istanbul Technical University, 34469 Istanbul, Turkey
*
Author to whom correspondence should be addressed.
Molecules 2017, 22(6), 793; https://doi.org/10.3390/molecules22060793
Submission received: 28 February 2017 / Revised: 27 April 2017 / Accepted: 9 May 2017 / Published: 24 May 2017
(This article belongs to the Special Issue Sulfonamides)
Browse Figures
Versions Notes

Abstract

:
Secondary sulfonamides (4a–8h) incorporating acetoxybenzamide, triacetoxybenzamide, hydroxybenzamide, and trihydroxybenzamide and possessing thiazole, pyrimidine, pyridine, isoxazole and thiadiazole groups were synthesized. Lactoperoxidase (LPO, E.C.1.11.1.7), as a natural antibacterial agent, is a peroxidase enzyme secreted from salivary, mammary, and other mucosal glands. In the present study, the in vitro inhibitory effects of some secondary sulfonamide derivatives (4a–8h) were examined against LPO. The obtained results reveal that secondary sulfonamide derivatives (4a–8h) are effective LPO inhibitors. The Ki values of secondary sulfonamide derivatives (4a–8h) were found in the range of 1.096 × 10−3 to 1203.83 µM against LPO. However, the most effective inhibition was found for N-(sulfathiazole)-3,4,5-triacetoxybenzamide (6a), with Ki values of 1.096 × 10−3 ± 0.471 × 10−3 µM as non-competitive inhibition.

1. Introduction

Sulfonamides constitute a privileged class among pharmacological agents by possessing properties including carbonic anhydrase enzyme (CA) inhibition, as well as diuretic, hypoglycemic, anticancer, antibacterial, antiviral, and metalloprotease inhibitory effects. Although many years passed since their first discovery in the 1930s as a chemotherapeutic agent for antibacterial properties they are receiving increasing attention due to their newly-discovered pharmacological properties [1,2,3,4,5]. Due to the belief that sulfonamides must be be primary sulfonamides to exhibit those pharmacological properties, secondary sulfonamides are more investigated from the synthetic view and have found less pharmacological applications. However, recent investigations shown that secondary sulfonamides have a great potential not only for their selective inhibition characteristics on CA isozymes [6,7,8] but also for their good inhibition properties over cancer-related CA isoenzymes [9], for anticandidal properties [10] and also for their glutamate carboxypeptidase II inhibition properties [11].
It was also reported that sulfonamides had a number of interesting functionalities. Some example can be given for secondary and tertiary and sulfonylureas represent particularly important structural motifs in several classes of drugs. Sulfonamides possessed some biological activities as antibiotics (sulfhamethoxazole), PDE5 inhibitors for the treatment of erectile dysfunction (sildenafil), protease inhibitor for treatment of HIV (darunavir), sulfonylureas for treatment of diabetes mellitus (glibenclamide), hepatitis C anti-viral RNA polymerase inhibitors, and non-steroidal anti-inflammatory COX-2 inhibitors (oxicam class) [12].
Because secondary sulfonamides have been reported to be effective agents, in this study, new designs of secondary sulfonamide drugs containing thiazole, pyrimidine, pyridine, isoxazole and thiadiazole moieties were utilized to obtain acetoxybenzamide, triacetoxybenzamide, hydroxybenzamide and trihydroxybenzamide sulfonamide derivatives to achieve the synergistic effects of sulfonamides and polyphenols in one molecule. Since acetyl protection of hydroxyl groups is a well-known application in pharmacology to enhance oral bioavailability and to increase therapeutic concentration of the drug in the bloodstream, both acetylated and non-acetylated forms of compounds were examined together.
Milk contains a variety of constituents that protect the neonate and the milk itself from a host of deleterious microorganisms. One of the constituents is the lactoperoxidase (LPO) system [13,14,15]. This system is a naturally-occurring antimicrobial system [16,17,18] which is inherently available in raw milk and human body fluids such as saliva. There are three primary components in the LPO system: haeme-containing LPO, hydrogen peroxide (H2O2), and thiocyanate (SCN−). H2O2 is produced by a number of microorganisms such as lactobacilli, Lactococcus and streptococci through enzymatic oxidation of some biomolecules including ascorbic acid and glucose [19,20,21]. Additionally, LPO is released from mucosal glands and can be found in secretions like saliva, milk or tears. The potential of LPO to inhibit bacterial growth in milk has been recognized [22,23]. LPO catalyses the H2O2-dependent oxidation of thiocyanate (SCN−) to hypothiocyanite (OSCN−). The latter ion is a potent antimicrobial agent against gram-negative and gram-positive bacteria, fungi, and viruses [16,24]. This reaction makes the LPO system potentially useful in improving food safety [16,25]. LPO has crucial applications in various fields. For example, LPO protects the intestinal tract system of newborn infants against pathogenic microorganisms by catalysing halides and pseudohalides. LPO is one of the important proteins in bovine whey, and it has been known to play a key role in protection of the lactating mammary gland and the intestinal tract of newborn infants against pathogenic microorganisms [26,27,28].
The aim of the present study was to assess the inhibition effects of a new class of secondary sulfonamides against LPO enzyme, one of the prominent enzymes generally found in several sources, such as bovine milk, saliva, and tears.

2. Materials and Methods

2.1. Chemicals and Materials

Fresh bovine milk was obtained from the local dairy. L-Tyrosine, Amberlite CG-50-NH4+ resin, CNBr-activated-Sepharose 4B, protein assay reagent sulfanilamide, and chemicals for electrophoresis were purchased from Sigma-Aldrich Co. (Sigma-Aldrich Chemie GmbH Export Department Eschenstrasse 5, 82024 Taufkirchen, Germany).

2.2. General Procedure for Sulfonamide Derivatives

Secondary sulfonamides were synthesized using naturally available 4-hydroxy and 3,4,5-trihydroxy benzoic acids (gallic acid) in various plants and fruits, which were reacted with acetic anhydride to obtain 4-acetoxy and 3,4,5-triacetoxy benzoic acids for the protection of hydroxyl groups. Then, they were converted to their corresponding chloride derivatives by treating with thionyl chloride to produce benzoyl chlorides, which underwent reactions with secondary sulfonamides having thiazole, pyrimidine, pyridine, isoxazole and thiadiazole groups to obtain secondary sulfonamide derivatives of acetoxybenzamides and triacetoxybenzamides as one part of target compounds. Deacetylation under acidic conditions gave the other part of our targeted sulfonamide derivatives [28]. The reaction scheme is given in Figure 1.

2.3. Biochemical Assays

LPO activities were determined by the procedure of Shindler and Bardsley [29] with slight modification [30,31]. This method is based on the oxidation of chromogenic substrate 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) by hydrogen peroxide (H2O2), which results in a product which had absorbance at 412 nm [32].
The affinity matrix was synthesised by coupling sulfanilamide as the ligand and l-tyrosine as the spacer arm to CNBr-activated-Sepharose 4B, following the previously published procedure [22] with a slight modification [33,34]. The protein flow in the column eluates was spectrophotometrically determined at 280 nm [35]. All purification steps were performed at 4 °C. The protein quantity was determined at 595 nm according to the Bradford method [36]. Bovine serum albumin was used as the standard protein [37,38,39]. For determination of LPO purity, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was used according to the procedure of Laemmli [40]. In this application, the imaging method was performed in 10% and 3% acrylamide for the running and the stacking gel, respectively, with 0.1% SDS [41,42,43].
The effects of secondary sulfonamide derivatives (4a–8h) on LPO purified from fresh bovine milk by affinity chromatography technique were previously determined [22]. In our study, LPO activity was measured in the presence of different concentrations of secondary sulfanilamide derivatives (4a–8h). A control sample without secondary sulfonamide was taken as 100%. An activity (%)-[Secondary sulfonamide] plot was drawn. For the determination of the inhibition constant (Ki) values, three different secondary sulfonamide derivative (4a–8h) concentrations were used. Additionally, ABTS was used as a substrate at five different concentrations. Lineweaver–Burk plots (1/V-1/[ABTS]) were obtained for secondary sulfonamide; the Ki and the inhibition type were calculated from these plots [44]. The data obtained were analysed by t-test and the results are given as Means ± SD.

3. Results and Discussion

Enzymes are biological macromolecules that accelerate or catalyse chemical reactions in biological systems [45,46]. At low concentrations, some chemicals and drugs alter normal enzyme activities by specific enzyme inhibitions [47,48]. On the other hand, sulfonamide derivative drugs were the first systemically used antibiotics and paved the way for the antibiotic revolution in medicine. They were also largely investigated by means of physiological, kinetic, and pharmacological studies [49,50,51]. In addition, these molecules are the most important and largely used zinc binding function for the design of CA isoenzymes inhibitors. It was highlighted that the sulfonamide groups are an ideal ligand for some enzyme active site [52,53].
Although sulfonamide derivatives are used in therapies, there has been no reported LPO activity for these synthesized compounds (4a–8h). As show in Table 1, LPO was separately purified from bovine milk by Sepharose 4B-l-tyrosine-sulfonamide affinity chromatography technique. The LPO was purified 407.0-fold with a specific activity of 24.45 EU/mg and overall yield of 75.6% (Table 1). The purification of LPO after Sepharose 4B-l-tyrosine-sulfonamide-affinity chromatography was controlled by SDS-PAGE and a single band was observed for LPO (Figure 2). For secondary sulfonamides (4a–8h), the inhibitor concentrations causing up to 50% inhibition (IC50 values) were determined from the regression analysis graphs. IC50 values obtained for LPO are shown in Table 2. From in vitro studies, it was understood that LPO was effectively inhibited by these secondary sulfonamide derivatives (4a–8h). The inhibition of LPO-catalysed iodination has sometimes been used for designing new antithyroid agents [45]. To understand the nature of LPO inhibition, kinetic experiments with different concentrations of secondary sulfonamides (4a–8h), varying the respective concentrations of the substrates ABTS for each concentration of the sulfonamide derivatives (4a–8h) were performed. The Lineweaver–Burk plots were obtained by plotting 1/v versus 1/[ABTS], which showed parallel lines for different concentrations of secondary sulfonamide derivatives (4a–8h). The lines do not intersect at a common point as shown in Table 2, indicating that secondary sulfonamide derivatives (4a–8h) inhibition effects against LPO are commonly non-competitive with respect to the ABTS substrates. In this assay, it was suggested that the secondary sulfonamides (4a–8h) do not directly react with LPO. However, any variation in the concentration of ABTS does not affect the reactivity of secondary sulfonamides (4a–8h). This is also reflected in the non-competitive nature of the inhibition by the compounds with respect to ABTS. The inhibition data of secondary sulfonamides (4a–8h) reported here are summarized in Table 2, and the following comments can be drawn from these data. Additionally, LPO inhibition by sulfonamide derivatives (4a–8h) is dependent on the positioning of the inhibitor in the active site; i.e., the distance between the atoms in the secondary sulfonamide derivatives (4a–8h) and active site amino acids.
All synthesized secondary sulfonamides derivatives (4a–8h) exhibited effective inhibitory activity against LPO, one of the prominent enzymes in milk, with a Ki values in the range of 1.096 × 10−3 ± 0.471 × 10−3–1203.83 ± 616.78 µM (Table 2). Additionally, N-(sulfathiazole)-3,4,5-triacetoxybenzamide (6a) demonstrated the most powerful LPO inhibition effect with low nanomolar Ki value (1.096 nM). On the other hand, among the synthesized secondary sulfonamides (4a–8h) N-(sulfadiazine)-p-acetoxy-benzamide (5b, 260 nM), N-(sulfamethazine)-p-acetoxybenzamide (5c, 80 nM), N-(sulfisoxazole) p-acetoxybenzamide (5e, 934 nM), N-(sulfamethizole)-p-acetoxybenzamide (5f, 324 nM), N-(sulfanilamide)-p-hydroxybenzamide (7h, 217 nM) and N-(sulfathiazole)-3,4,5-trihydroxybenzamide (8a, 25 nM), showed effective inhibition profiles against bovine milk LPO. Additionally, in general, the acetylated sulfonamides are better inhibitors than the non-acetylated sulfonamides, although the acetylated acids are poorer inhibitors than the non-acetylated acids.

4. Conclusions

Secondary sulfonamides incorporating acetoxybenzamide, triacetoxybenzamide, hydroxybenzamide and trihydroxybenzamide–all possessing thiazole, pyrimidine, pyridine, isoxazole and thiadiazole groups–were synthesized, and biological activities were evaluated. Milk is a vital liquid secreted from the mammary glands of females of all mammal species. So, the inhibition of the LPO is very important in terms of the LPO system, which catalyses the oxidation of several different reactions by H2O2 of a large range of substrates, such as the oxidation of endogenous thiocyanate (SCN−) to the antibacterial hypothiocyanite (OSCN−). Secondary sulfonamides (4a–8h) have shown micromolar to nanomolar inhibition against LPO that is vital activity for the innate immune system because of removing bacteria from milk and mucosal secretions. If LPO activity is reduced, this means that the immune system is weakened. This is particularly undesirable, since this affects the immune system of infants that used sulfonamides as a drug.

Author Contributions

Y.C. and H.U. purified lactoperoxidase enzyme from bovine milk by Sepharose 4B-l-tyrosine-sulfonamide affinity chromatography. Z.K., R.K. and Z.A. determined the inhibition effects of sulfonamide derivatives on LPO enzyme. T.G. and A.C.G. synthesised secondary sulfonamide derivatives. I.G. and H.O. participated in the study design and coordination, and drafted the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Supuran, C.T.; Innocenti, A.; Mastrolorenzo, A.; Scozzafava, A. Antiviral sulfonamide derivatives. Mini Rev. Med. Chem. 2004, 4, 189–200. [Google Scholar] [CrossRef] [PubMed]
  2. Göçer, H.; Akıncıoğlu, A.; Öztaşkın, N.; Göksu, S.; Gülçin, İ. Synthesis, antioxidant and antiacetylcholinesterase activities of sulfonamide derivatives of dopamine related compounds. Arch. Pharm. 2013, 346, 783–792. [Google Scholar]
  3. Akbaba, Y.; Akıncıoğlu, A.; Göçer, H.; Göksu, S.; Gülçin, İ.; Supuran, C.T. Carbonic anhydrase inhibitory properties of novel sulfonamide derivatives of aminoindanes and aminotetralins. J. Enzyme Inhib. Med. Chem. 2014, 29, 35–42. [Google Scholar] [CrossRef] [PubMed]
  4. Akıncıoğlu, A.; Topal, M.; Gülçin, İ.; Göksu, S. Novel sulfamides and sulfonamides incorporating tetralin scaffold as carbonic anhydrase and acetylcholine esterase inhibitors. Arch. Pharm. 2014, 347, 68–76. [Google Scholar]
  5. Gokcen, T.; Al, M.; Topal, M.; Gülçin, I.; Ozturk, T.; Goren, A.C. Synthesis of some natural sulphonamide derivatives as carbonic anhydrase inhibitors. Org. Commun. 2017, 10, 15–23. [Google Scholar]
  6. Ivanova, J.; Carta, F.; Vullo, D.; Leitans, J.; Kazaks, A.; Tars, K.; Žalubovskis, R.; Supuran, C.T. N-Substituted and ring opened saccharin derivatives selectively inhibit transmembrane, tumor-associated carbonic anhydrases IX and XII. Bioorg. Med. Chem. 2017. [Google Scholar] [CrossRef] [PubMed]
  7. Carta, F.; Birkmann, A.; Pfaff, T.; Buschmann, H.; Schwab, W.; Zimmermann, H.; Maresca, A.; Supuran, C.T. Lead development of thiazoylsulfonamides with carbonic anhydrase inhibitory action. J. Med. Chem. 2017, 60, 3154–3164. [Google Scholar] [CrossRef] [PubMed]
  8. Petrou, A.; Geronikaki, A.; Terzi, E.; Guler, O.O.; Tiziano, T.; Supuran, C.T. Inhibition of carbonic anhydrase isoforms I, II, IX, and XII with secondary sulphonamides incorporating benzothiazole scaffolds. J. Enzyme Inhib. Med. Chem. 2016, 31, 1306–1311. [Google Scholar] [CrossRef] [PubMed]
  9. Moeker, J.; Peat, T.S.; Bornaghi, L.F.; Vullo, D.; Supuran, C.T.; Poulsen, S.A. Cyclic secondary sulfonamides: Unusually good inhibitors of cancer-related carbonic anhydrase enzymes. J. Med. Chem. 2014, 57, 3522–3531. [Google Scholar] [CrossRef] [PubMed]
  10. Qandil, A.M.; Hassan, M.A.; Al-Shar’i, N.A. Synthesis and anticandidal activity of azole-containing sulfonamides. Arch. Pharm. 2008, 341, 99–112. [Google Scholar] [CrossRef] [PubMed]
  11. Blank, B.R.; Alayoğlu, P.; Engen, W.; Choi, J.K.; Berkman, C.E.; Anderson, M.O. N-Substituted glutamyl sulphonamides as inhibitors of glutamate carboxypeptidase II (GCP2). Chem. Biol. Drug. Des. 2011, 77, 241–247. [Google Scholar] [CrossRef] [PubMed]
  12. Burhop, A.; Weck, R.; Atzrodt, J.; Derdau, V. Hydrogen-isotope exchange (HIE) reactions of secondary and tertiary sulfonamides and sulfonylureas with iridium (I) catalysts. Eur. J. Org. Chem. 2017, 11, 1418–1424. [Google Scholar] [CrossRef]
  13. Ueda, T.; Sakamaki, K.; Kuroki, T.; Yano, I.; Nagata, S. Molecular cloning and characterization of the chromosomal gene for human lactoperoxidase. Eur. J. Biochem. 1976, 243, 32–41. [Google Scholar] [CrossRef]
  14. Şişecioğlu, M.; Çankaya, M.; Gülçin, İ.; Özdemir, M. The Inhibitory effect of propofol on lactoperoxidase. Protein Pept. Lett. 2009, 16, 46–49. [Google Scholar]
  15. Şişecioğlu, M.; Çankaya, M.; Gülçin, İ.; Özdemir, M. Interactions of melatonin and serotonin to lactoperoxidase enzyme. J. Enzyme Inhib. Med. Chem. 2010, 25, 779–783. [Google Scholar]
  16. Elliot, R.M.; McLay, J.C.; Kennedy, M.J.; Simmonds, R.S. Inhibition of foodborne bacteria by the lactoperoxidase system in a beef cube system. Int. J. Food Microbiol. 2004, 91, 73–81. [Google Scholar] [CrossRef]
  17. Şişecioğlu, M.; Kireçci, E.; Çankaya, M.; Özdemir, H.; Gülçin, İ.; Atasever, A. The prohibitive effect of lactoperoxidase system (LPS) on some pathogen fungi and bacteria. Afr. J. Pharm. Pharmacol. 2010, 4, 671–677. [Google Scholar]
  18. Şişecioğlu, M.; Gülçin, İ.; Çankaya, M.; Atasever, A.; Özdemir, H. The effects of norepinephrine on lactoperoxidase enzyme (LPO). Sci. Res. Essays 2010, 5, 1351–1356. [Google Scholar]
  19. Jooyandeh, H.; Aberoumand, A.; Nasehi, B. Application of lactoperoxidase system in fish and food products: A review. Am. Eurasian J. Agric. Environ. Sci. 2011, 10, 89–96. [Google Scholar]
  20. Şişecioğlu, M.; Uguz, M.T.; Çankaya, M.; Özdemir, H.; Gülçin, İ. Effects of ceftazidime pentahydrate, prednisolone, amikacin sulfate, ceftriaxone sodium and teicoplanin on bovine milk lactoperoxidase activity. Int. J. Pharmacol. 2011, 7, 79–83. [Google Scholar]
  21. Şişecioğlu, M.; Gülçin, İ.; Çankaya, M.; Özdemir, H. The inhibitory effects of L-Adrenaline on lactoperoxidase enzyme (LPO) purified from buffalo milk. Int. J. Food Propert. 2012, 15, 1182–1189. [Google Scholar]
  22. Munsch-Alatossava, P.; Quintyn, R.; De Man, I.; Alatossava, T.; Gauchi, J.P. Efficiency of N2 gas flushing compared to the lactoperoxidase system at controlling bacterial growth in bovine raw milk stored at mild temperatures. Front. Microbiol. 2016, 7, 839. [Google Scholar] [CrossRef] [PubMed]
  23. Atasever, A.; Özdemir, H.; Gülçin, İ.; Küfrevioğlu, Ö.İ. One-step purification of lactoperoxidase from bovine milk by affinity chromatography. Food Chem. 2013, 136, 864–870. [Google Scholar] [CrossRef] [PubMed]
  24. Köksal, Z.; Usanmaz, H.; Özdemir, H.; Gülçin, İ.; Güney, M. Inhibition effects of some phenolic and dimeric phenolic compounds on bovine lactoperoxidase (LPO) enzyme. Int. J. Acad. Res. 2014, 6, 27–32. [Google Scholar]
  25. Golmohamadi, A.; Morra, M.J.; Popova, I.; Nindo, C.I. Optimizing the use of Sinapis alba seed meal extracts as a source of thiocyanate (SCN−) for the lactoperoxidase system. Lebensm. Wiss. Technol. 2016, 72, 416–422. [Google Scholar] [CrossRef]
  26. Ozturk Sarikaya, S.B.; Sisecioglu, M.; Cankaya, M.; Gülçin, İ.; Ozdemir, H. Inhibition profile of a series of phenolic acids on bovine lactoperoxidase enzyme. J. Enzyme Inhib. Med. Chem. 2015, 30, 479–483. [Google Scholar] [CrossRef] [PubMed]
  27. Koksal, Z.; Kalın, R.; Gülçin, İ.; Özdemir, H.; Atasever, A. The impact of some avermectins on lactoperoxidase from bovine milk. Int. J. Food Propert. 2016, 19, 1207–1216. [Google Scholar] [CrossRef]
  28. Gokcen, T.; Gülçin, İ.; Ozturk, T.; Goren, A.C. A Class of Sulfonamides as carbonic anhydrase inhibitor. J. Enzyme Inhib. Med. Chem. 2016, 31, 180–188. [Google Scholar] [CrossRef] [PubMed]
  29. Shindler, J.S.; Bardsley, W. Steady-state kinetics of lactoperoxidase with ABST as chromogens. Biochem. Biophys. Res. Comm. 1975, 67, 1307–1312. [Google Scholar] [CrossRef]
  30. Jacob, B.M.; Anthony, K.E.; Sreekumar, B.; Haridas, M. Thiocyanate mediated antifungal and antibacterial property of goat milk lactoperoxidase. Life Sci. 2000, 66, 2433–2439. [Google Scholar] [CrossRef]
  31. Gülçin, İ.; Scozzafava, A.; Supuran, C.T.; Akıncıoğlu, H.; Koksal, Z.; Turkan, F.; Alwasel, S. The effect of caffeic acid phenethyl ester (CAPE) metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, glutathione s-transferase, lactoperoxidase and carbonic anhydrase ısoenzymes I, II, IX and XII. J. Enzyme Inhib. Med. Chem. 2016, 31, 1095–1101. [Google Scholar]
  32. Gülçin, İ.; Scozzafava, A.; Supuran, C.T.; Koksal, Z.; Turkan, F.; Çetinkaya, S.; Bingöl, Z.; Huyut, Z.; Alwasel, S.H. Rosmarinic acid inhibits some metabolic enzymes including glutathione S-transferase, lactoperoxidase, acetylcholinesterase, butyrylcholinesterase, and carbonic anhydrase isoenzymes. J. Enzyme Inhib. Med. Chem. 2016, 31, 1698–1702. [Google Scholar]
  33. Cuatrecasa, P. Protein purification by affinity chromatography. J. Biol. Chem. 1970, 245, 3059–3065. [Google Scholar]
  34. Arslan, O.; Nalbantoglu, B.; Demir, N.; Ozdemir, H.; Kufrevioglu, O.I. A new method for the purification of carbonic anhydrase isozymes by affinity chromatography. Turk. J. Med. Sci. 1996, 26, 163–166. [Google Scholar]
  35. Boztaş, M.; Çetinkaya, Y.; Topal, M.; Gülçin, İ.; Menzek, A.; Şahin, E.; Tanc, M.; Supuran, C.T. Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxy-bromophenol derivatives incorporating cyclopropane moieties. J. Med. Chem. 2015, 58, 640–650. [Google Scholar]
  36. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–251. [Google Scholar] [CrossRef]
  37. Yıldırım, A.; Atmaca, U.; Keskin, A.; Topal, M.; Çelik, M.; Gülçin, İ.; Supuran, C.T. N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II. Bioorg. Med. Chem. 2015, 23, 2598–2605. [Google Scholar]
  38. Aydin, B.; Gülcin, I.; Alwasel, S.H. Purification and characterization of polyphenol oxidase from Hemşin apple (Malus communis L.). Int. J. Food Propert. 2015, 18, 2735–2745. [Google Scholar] [CrossRef]
  39. Arabaci, B.; Gülçin, İ.; Alwasel, S. Capsaicin: A potent inhibitor of carbonic anhydrase isoenzymes. Molecules 2014, 19, 10103–10114. [Google Scholar] [CrossRef] [PubMed]
  40. Laemmli, D.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1975, 227, 680–685. [Google Scholar] [CrossRef]
  41. Göksu, S.; Naderi, A.; Akbaba, Y.; Kalın, P.; Akıncıoğlu, A.; Gulcin, İ.; Durdaği, S.; Salmas, R.E. Carbonic anhydrase inhibitory properties of novel benzylsulfamides using molecular modeling and experimental studies. Bioorg. Chem. 2014, 56, 75–82. [Google Scholar]
  42. Güney, M.; Coşkun, A.; Topal, F.; Daştan, A.; Gülçin, İ.; Supuran, C.T. Oxidation of cyanobenzocycloheptatrienes: Synthesis, photooxygenation reaction and carbonic anhydrase isoenzymes inhibition properties of some new benzotropone derivatives. Bioorg. Med. Chem. 2014, 22, 3537–3543. [Google Scholar]
  43. Topal, M.; Gülçin, İ. Rosmarinic acid: A potent carbonic anhydrase isoenzymes inhibitor. Turk. J. Chem. 2014, 38, 894–902. [Google Scholar] [CrossRef]
  44. Lineweaver, H.; Burk, D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 1934, 56, 658–666. [Google Scholar] [CrossRef]
  45. Aksu, K.; Nar, M.; Tanç, M.; Vullo, D.; Gülçin, İ.; Göksu, S.; Tümer, F.; Supuran, C.T. The synthesis of sulfamide analogues of dopamine related compounds and their carbonic anhydrase inhibitory properties. Bioorg. Med. Chem. 2013, 21, 2925–2931. [Google Scholar] [CrossRef] [PubMed]
  46. Gülçin, İ.; Beydemir, S. Phenolic compounds as antioxidants: Carbonic anhydrase isoenzymes inhibitors. Mini Rev. Med. Chem. 2013, 13, 408–430. [Google Scholar]
  47. Akıncıoğlu, A.; Akbaba, Y.; Göçer, H.; Göksu, S.; Gülçin, İ.; Supuran, C.T. Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors. Bioorg. Med. Chem. 2013, 21, 1379–1385. [Google Scholar]
  48. Öztürk, Sarı; kaya, S.B.; Topal, F.; Şentürk, M.; Gülçin, İ.; Supuran, C.T. In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds. Bioorg. Med. Chem. Lett. 2011, 21, 4259–4262. [Google Scholar]
  49. Temperini, C.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct-An inhibitor mimicking the sulfonamide and urea binding to the enzyme. Bioorg. Med. Chem. Lett. 2010, 20, 474–478. [Google Scholar] [CrossRef] [PubMed]
  50. Thiry, A.; Dogné, J.M.; Supuran, C.T.; Masereel, B. Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: Drug design and mechanism of action. Curr. Pharm. Des. 2008, 14, 661–671. [Google Scholar] [PubMed]
  51. Alterio, V.; Di Fiore, A.; D’Ambrosio, K.; Supuran, C.T.; De Simone, G. Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms? Chem. Rev. 2012, 112, 4421–4468. [Google Scholar] [CrossRef] [PubMed]
  52. Topal, F.; Gülçin, İ.; Dastan, A; Guney, M. Novel eugenol derivatives: Potent acetylcholinesterase and carbonic anhydrase inhibitors. Int. J. Biol. Macromol. 2017, 94, 845–851. [Google Scholar] [CrossRef] [PubMed]
  53. Kirthana, M.V.; Khan, F.N.; Sivakumar, P.M.; Doble, M.; Manivel, P.; Prabakaran, K.; Krishnakumar, V. Antithyroid agents and QSAR studies: Inhibition of lactoperoxidase-catalyzed iodination reaction by isochromene-1-thiones. Med. Chem. Res. 2013, 22, 4810–4817. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 22 00793 g001 550
Figure 1. The synthesis route of targeted secondary sulfonamide derivatives (1a–8h).
Figure 1. The synthesis route of targeted secondary sulfonamide derivatives (1a–8h).
Molecules 22 00793 g001
Molecules 22 00793 g002 550
Figure 2. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) band of LPO. Columns a, b and c are purified LPO from bovine milk by affinity column chromatography. Column d is standard proteins (Line 1: 250 kDa, Line 2: 150 kDa, Line 3: 100 kDa, Line 4: 70 kDa, Line 5: 50 kDa, Line 6: 40 kDa, Line 7: 30 kDa, Line 8: 20 kDa).
Figure 2. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) band of LPO. Columns a, b and c are purified LPO from bovine milk by affinity column chromatography. Column d is standard proteins (Line 1: 250 kDa, Line 2: 150 kDa, Line 3: 100 kDa, Line 4: 70 kDa, Line 5: 50 kDa, Line 6: 40 kDa, Line 7: 30 kDa, Line 8: 20 kDa).
Molecules 22 00793 g002
Table
Table 1. Purification of lactoperoxidase (LPO) from bovine milk by Sepharose 4B-l-tyrosine-sulfonamide affinity chromatography.
Table 1. Purification of lactoperoxidase (LPO) from bovine milk by Sepharose 4B-l-tyrosine-sulfonamide affinity chromatography.
Purification StepsTotal Volume (mL)Enzyme Activity (EU/mL)Total Enzyme Activity (EU/mL·min)Protein (mg/mL)Total Protein (mg)Specific Activity (EU/mg)Yield (%)Purification Fold
Homogenate60.01.060.015.0900.00.061001.00
Sepharose 4B-l-tyrosine-sulfonamide10.04.545.00.1841.8424.4575.6407.0
Table
Table 2. The inhibition types, IC50 and Ki values of some secondary sulfonamide derivatives (4a–8h) on LPO purified from bovine milk.
Table 2. The inhibition types, IC50 and Ki values of some secondary sulfonamide derivatives (4a–8h) on LPO purified from bovine milk.
No.Compound NamesIC50 (µM)Ki (µM)Inhibition Type
4aSulfathiazole231.0038.43 ± 6.06Non-competitive
4bSulfadiazine92.2490.66 ± 2.52Non-competitive
4cSulfamethazine346.50198.00 ± 24.46Non-competitive
4dSulfapyridine227.0065.00 ± 3.61Competitive
4eSulfisoxazole221.70182.66 ± 34.07Non-competitive
4fSulfamethizole115.5021.18 ± 5.66Non-competitive
4gSulfamerazine18.7320.52 ± 2.14Non-competitive
4hSulfanilamide8.4835.70 ± 4.88Competitive
5aN-(sulfathiazole)-p-acetoxybenzamide99.0056.06 ± 23.56Non-competitive
5bN-(sulfadiazine)-p-acetoxybenzamide0.0150.026 ± 0.004Non-competitive
5cN-(sulfamethazine)-p-acetoxybenzamide0.0100.008 ± 0.003Competitive
5dN-(sulfapyridine)-p-acetoxybenzamide10.0449.15 ± 19.99Competitive
5eN-(sulfisoxazole)-p-acetoxybenzamide3.030.934 ± 0.357Competitive
5fN-(sulfamethizole)-p-acetoxybenzamide0.2380.324 ± 0.115Non-competitive
5gN-(sulfamerazine)-p-acetoxybenzamide3.9413.39 ± 6.19Competitive
5hN-(sulfanilamide)-p-acetoxybenzamide3.0532.29 ± 1.02Non-competitive
6aN-(sulfathiazole)-3,4,5-triacetoxybenzamide0.656 × 10−31.096 × 10−3 ± 0.471 × 10−3Non-competitive
6bN-(sulfadiazine)-3,4,5-triacetoxybenzamide13.862.90 ± 1.13Competitive
6cN-(sulfamethazine)-3,4,5-triacetoxybenzamide138.60152.03 ± 48.69Non-competitive
6dN-(sulfapyridine)-3,4,5-triacetoxybenzamide1.561.39 ± 0.15Non-competitive
6eN-(sulfisoxazole)-3,4,5-triacetoxybenzamide2.031.07 ± 0.02Competitive
6fN-(sulfamethizole)-3,4,5-triacetoxybenzamide6.668.55 ± 1.45Non-competitive
6gN-(sulfamerazine)-3,4,5-triacetoxybenzamide1.281.49 ± 0.28Non-competitive
6hN-(sulfanilamide)-3,4,5-triacetoxybenzamide3.052.29 ± 0.98Non-competitive
7aN-(sulfathiazole)-p-hydroxybenzamide15.066.85 ± 1.81Non-competitive
7bN-(sulfadiazine)-p-hydroxybenzamide0.0400.044 ± 0.022Noncompetitive
7cN-(sulfamethazine)-p-hydroxybenzamide0.4260.484 ± 0.146Non-competitive
7dN-(sulfapyridine)-p-hydroxybenzamide2.961.41 ± 0.13Competitive
7eN-(sulfisoxazole)-p-hydroxybenzamide10.8315.08 ± 3.90Non-competitive
7fN-(sulfamethizole)-p-hydroxybenzamide0.7990.387 ± 0.150Competitive
7gN-(sulfamerazine)-p-hydroxybenzamide1.7593.939 ± 1.098Non-competitive
7hN-(sulfanilamide)-p-hydroxybenzamide0.2850.217 ± 0.099Non-competitive
8aN-(sulfathiazole)-3,4,5-trihydroxybenzamide0.0140.025 ± 0.010Competitive
8bN-(sulfadiazine)-3,4,5-trihydroxybenzamide0.7151.292 ± 0.465Non-competitive
8cN-(sulfamethazine)-3,4,5-trihydroxybenzamide2.532.17 ± 0.88Competitive
8dN-(sulfapyridine)-3,4,5-trihydroxybenzamide10.195.85 ± 1.28Competitive
8eN-(sulfisoxazole)-3,4,5-trihydroxybenzamide1.991.44 ± 0.52Competitive
8fN-(sulfamethizole)-3,4,5-trihydroxybenzamide173.25292.78 ± 61.96Non-competitive
8gN-(sulfamerazine)-3,4,5-trihydroxybenzamide1.4843.87 ± 0.43Non-competitive
8hN-(sulfanilamide)-3,4,5-trihydroxybenzamide1.7823.104 ± 0.578Non-competitive

Share and Cite

MDPI and ACS Style

Köksal, Z.; Kalin, R.; Camadan, Y.; Usanmaz, H.; Almaz, Z.; Gülçin, İ.; Gokcen, T.; Gören, A.C.; Ozdemir, H. Secondary Sulfonamides as Effective Lactoperoxidase Inhibitors. Molecules 2017, 22, 793. https://doi.org/10.3390/molecules22060793

AMA Style

Köksal Z, Kalin R, Camadan Y, Usanmaz H, Almaz Z, Gülçin İ, Gokcen T, Gören AC, Ozdemir H. Secondary Sulfonamides as Effective Lactoperoxidase Inhibitors. Molecules. 2017; 22(6):793. https://doi.org/10.3390/molecules22060793

Chicago/Turabian Style

Köksal, Zeynep, Ramazan Kalin, Yasemin Camadan, Hande Usanmaz, Züleyha Almaz, İlhami Gülçin, Taner Gokcen, Ahmet Ceyhan Gören, and Hasan Ozdemir. 2017. "Secondary Sulfonamides as Effective Lactoperoxidase Inhibitors" Molecules 22, no. 6: 793. https://doi.org/10.3390/molecules22060793

APA Style

Köksal, Z., Kalin, R., Camadan, Y., Usanmaz, H., Almaz, Z., Gülçin, İ., Gokcen, T., Gören, A. C., & Ozdemir, H. (2017). Secondary Sulfonamides as Effective Lactoperoxidase Inhibitors. Molecules, 22(6), 793. https://doi.org/10.3390/molecules22060793

Article Metrics

Back to TopTop